S G O'Brien - Concepedia

Author

S G O'Brien

Newcastle University

Also Known As

S G O'Brien, S. G. O'Brien, S. G. O’Brien, S. G. O′Brien, S.G O'Brien, S.G. O’Brien, S.G. O’brien, Stephen G O'Brien

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Newcastle University University of Chicago Novartis (Switzerland)Royal Victoria Infirmary Oregon Health & Science University

About

S G O'Brien is an author at Newcastle University specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	1.1K
2	Health Sciences	3	3	904
3	Immunology	3	3	133
4	Gastroenterology	1	1	47
5	Hepatology	1	1	47

S G O'Brien

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Andreas Hochhaus, S G O'Brien, François Guilhot, Leukemia Hematological MalignancyChronic Myeloid LeukemiaMedicineHematologyMyeloid Neoplasia	2009	842
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia S G O'Brien, P Meinhardt, Epperson E. Bond, British Journal of Cancer	2003	154
Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa David Marín, Sarah Marktel, M Bua, Leukemia Chronic PhasePrognostic FactorsHematological MalignancyMedicineMixed-phenotype Acute Leukemia	2003	71
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia E. Feldman, Jörge E. Cortes, Daniel J. DeAngelo, Leukemia Hematological MalignancyChronic Myelomonocytic LeukemiaMyelodysplastic SyndromeMedicineMixed-phenotype Acute Leukemia	2008	60
High rates of durable response are achieved with imatinib after treatment with interferon plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial François Guilhot, Brian Druker, Richard A. Larson, Haematologica	2009	49
Chronic intrahepatic cholestasis in sickle cell disease requiring exchange transfusion. Adrian O’Callaghan, S G O'Brien, Mary Ninkovic, Gut Sickle Cell DiseaseHepatologyExchange TransfusionBiliary TractLiver Physiology	1995	47
Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia Anne M. Dickinson, Kim Pearce, Jean Norden, Haematologica	2010	27
A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP). Hagop M. Kantarjian, Norbert Gattermann, Andreas Hochhaus, Blood	2006	21
A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib Lucy C. Crossman, Thomas O’Hare, Thoralf Lange, Leukemia Allelic VariantCoding RegionSingle Nucleotide PolymorphismGenetic DisorderMedicine	2005	18
A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP) Philipp D. le Coutre, Oliver G. Ottmann, Norbert Gatterman, Journal of Clinical Oncology Accelerated PhaseMixed-phenotype Acute LeukemiaImmunologyPhase Ii StudyChronic Myelogenous Leukemia	2006	15

Page 1